EUCTR2019-004613-14-PL进行中（未招募）1 期
A prospective, multicenter, phase II trial to assess the efficacy and safety of MRD-driven treatment with VEnetoclax and RItuximab combination in previously unTreated pAtients with chronic lymphocytic leukemia (VERITA PALG-CLL5 study) - VERITA PALG-CLL5
POLISH ADULT LEUKEMIA GROUP0 个研究点目标入组 103 人开始时间: 2021年9月28日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 103
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed Informed Consent Form.
- •2. Ability and willingness to comply with the requirements of the study protocol.
- •3. Patient must have diagnosis of CLL or SLL that meets published 2018 IWCLL NCI-WG criteria.
- •4. No prior treatment for CLL or SLL including chemotherapy, BTK inhibitor therapy, venetoclax, small molecule signaling inhibitor, or monoclonal antibody therapy.
- •5. Patient must have an indication for treatment according to published 2018 IWCLL NCI-WG criteria.
- •6. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance score of = 2.
- •7. Adequate hematologic function independent of growth factor or transfusion support, per local laboratory reference range at screening (unless caused by underlying disease, as established by extensive bone marrow involvement or as a result of hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator) defined as follows:
- •o Hemoglobin = 9 g/dL
- •o Absolute neutrophil count = 1.0 x 109/L
- •o Platelet count = 50 × 109/L
- •8. Adequate renal function, per local laboratory reference range at screening, as indicated by:
- •o Calculated creatinine clearance = 30 mL/min using 24-hour creatinine clearance or modified Cockcroft-Gault equation (eCCR; with the use of ideal body mass [IBM] instead of mass).
- •9. Adequate liver function, per local laboratory reference range at screening, as indicated by:
- •o AST and ALT = 2.5 × ULN
- •o Total bilirubin = 1.5 × ULN (or = 3 × ULN for patients with documented Gilbert syndrome).
- •10. No active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment. Patients who have a positive Coombs test but no evidence of hemolysis are NOT excluded from participation.
- •11. No current use of corticosteroids. EXCEPTION: Low doses of steroids (< 10 mg of prednisone or equivalent dose of other steroid) used for treatment of non-hematologic medical condition (e.g. chronic adrenal insufficiency) is permitted.
- •12. No previous autoimmune complications (e.g. autoimmune hemolytic anemia or immune thrombocytopenia) that have developed since the initial diagnosis of CLL and have required treatment with high dose corticosteroids (e.g. equivalent of > 20 mg/day of prednisone), monoclonal antibody-based therapy, or chemotherapy. Prior use of corticosteroids for reasons other than treatment of autoimmune complications of CLL is allowed.
- •13. No major surgery within 4 weeks (28 days) of first dose of study drug or minor surgery within 3 days of first dose of study drug.
- •14. No radiation therapy = 4 weeks prior to study treatment initiation.
- •15. Patient must be able to receive xanthine oxidase inhibitor or rasburicase for tumor lysis syndrome (TLS) prophylaxis.
- •16. Negative pregnancy test (serum ßHCG) for women of childbearing potential (including pre-menopausal women who have had a tubal ligation) and for all women not meeting the definition of postmenopausal (= 24 months of amenorrhea), and who have not undergone surgical sterilization with a hysterectomy and/or bilateral oophorectomy. For all other women, documentation must be present in medical history confirming that the patient is not of childbearing potential.
- •o Female patients who are not surgically sterile or postmenopausal must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the study.
- •o Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential w
排除标准
- •1. Richter's transformation confirmed by biopsy.
- •2. History of other malignancy that could affect compliance with the protocol or interpretation of results
- •o Patients with a history of curatively treated basal or squamous cell carcinoma or Stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible.
- •o Patients with a malignancy that has been treated with surgery alone with curative intent will be included. Individuals in documented remission without treatment for = 2 years prior to enrollment may be included at the discretion of the investigator.
- •3. Uncontrolled active systemic infection (viral, bacterial, and fungal).
- •4. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection confirmed by polymerase chain reaction (PCR) test from respiratory tract specimen (e.g. nasopharyngeal swab).
- •5. Known positive serology for human immunodeficiency virus (HIV), due to potential drug-drug interactions between anti-retroviral medications and the study drugs.
- •6. Active hepatitis C, defined by the detectable hepatitis C ribonucleic acid (RNA) in plasma by polymerase chain reaction (PCR).
- •7. Patient is pregnant or breast-feeding.
- •8. Malabsorption syndrome or other condition that precludes enteral route of administration.
- •9. An individual organ/system impairment score of 4 as assessed by the CIRS definition limiting the ability to receive the treatment regimen of this trial with the exception of eyes, ears, nose, throat organ system (note that symptoms related to CLL should not be included in the patient’s screening CIRS score). Investigators should consult the General Rules for Severity Rating as well as the Organ-Specific Categories when assigning scores for certain conditions (i.e., pulmonary embolism) and consider the level of morbidity associated with a patient’s condition.
- •10. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and/or would make the patient inappropriate for enrollment into this study.
- •11. Patients who have received strong and moderate CYP3A inhibitors and/or CYP3A inducers within 7 days prior to the first dose of venetoclax, patients who consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax.
- •12. Patients require use of warfarin (due to potential drug-drug interactions that may potentially increase the exposure of warfarin). Patients may be eligible if able to be taken off warfarin and started on an alternative anticoagulant.
- •13. Patients with evidence any of the following conditions:
- •o New York Heart Association Functional Classification III or IV congestive heart failure
- •o History of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to registration
- •o Recent infection requiring systemic treatment; need to have completed anti-biotic therapy > 14 days before the first dose of study drug
- •o Cerebral vascular accident or intracranial bleed within the last 6 months
- •o Known active chronic hepatitis C
- •Positive serology for hepatitis B defined as a positive test for hepatitis B surface antigen (HBsAg); in addition, if negative for HBsAg but hepatitis B core antibody (HBcAb) positive (regardless of hepatitis B surface an
研究者
相似试验
进行中（未招募）
1 期
A randomized, multi-center phase II trial to assess the efficay of 5-azacytidine added to standard primery therapy in elderly patients with newly diagnosed AML. - AML-AZAThe disease under investigation is newly diagnosed Acute Myeloid Leucemia (AML) in elderly patients.MedDRA version: 13.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-004583-40-DEniversitaetsklinikum Muenster234
已完成
2 期
The safety of Cpn10 in patients with multiple sclerosisNeurological - Multiple sclerosisMultiple SclerosisACTRN12606000037505CBio Limited50
进行中（未招募）
2 期
A prospective, multicenter phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients with relapsed/refractory transformed aggressive LymphomaC83.3Diffuse large B-cell lymphomaDRKS00023793niversitätsmedizin der Johannes Gutenberg-Universität Mainz26
进行中（未招募）
1 期
A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma.Malignant B-cell lymphomaMedDRA version: 21.0Level: PTClassification code 10003903Term: B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002373-59-DEniversity Medical Center of the Johannes Gutenberg University Mainz64
未知
2 期
A Phase II, Multicenter, Clinical Trial to Evaluate The Efficacy and Safety of Bevacizumab in Recurrent Malignant GliomaMalignant gliomaJPRN-jRCT2080220811Chugai Pharmaceutical Co., Ltd.31